Please contact us for more information or to learn if you are eligible to participate.
To evaluate the effect of EFX compared to placebo on fibrosis regression in NASH subjects with stage 2 or 3 fibrosis.
Fernando Membreno, MD
Akero Therapeutics, Inc.
Type of Trial